Research programme: galectin inhibitors - La Jolla Pharmaceutical

Drug Profile

Research programme: galectin inhibitors - La Jolla Pharmaceutical

Alternative Names: Galectin antagonists - La Jolla Pharmaceutical; Galectin-3 inhibitors - La Jolla Pharmaceutical; LJPC-201; LJPC-301

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Class Monoclonal antibodies; Small molecules
  • Mechanism of Action Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Heart failure; Hepatic fibrosis; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Solid-tumours in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Heart-failure in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for research development in Hepatic-fibrosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top